Given the lack of clear therapeutic targets for HER2‐negative breast cancer patients, and the significant role of m7G regulatory genes in disease onset and progression, we investigated m7G regulatory gene expression patterns in HER2‐negative breast cancer patients to identify new prognostic markers and therapeutic targets. This evidence concerns the gene ERBB2 and breast cancer.